The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.
The user shared progress after 9 months of using finasteride, minoxidil, and dermarolling for hair loss, despite some inconsistency in treatment. They are pleased with the results and plan to stop updating.
A user reported positive results using finasteride 1.25mg daily for six years with no side effects, highlighting early treatment benefits. Others discussed experiences with finasteride, minoxidil, and dutasteride, mentioning different side effects and effectiveness.
Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.
Despite using finasteride and dutasteride for years, the user experienced continued hair thinning and is now visibly balding. They are considering trying minoxidil but are doubtful about its effectiveness.
User asks about CB-03-01 for hair loss treatment and mentions using topical Dutasteride, TRT, and considering mixing CB-03-01 with Fluridil. CB-03-01 is sold at a high price, and user considers trying a lower concentration.
The conversation is about experiences with Kintor's KX-826 for hair loss, specifically regarding side effects. Some users reported side effects from grey market versions, questioning their authenticity.
A user is seeking help to purchase and ship Alpecin DMG to the United States due to issues with eBay sellers. They prefer Alpecin DMG over minoxidil because of concerns about minoxidil's effects on insulin production, as they have diabetes.
The user experienced significant hair regrowth using a combination of oral minoxidil (5mg) and dutasteride (0.5mg) along with monthly mesotherapy injections. Despite the progress, the user plans to proceed with a hair transplant to address a receding hairline that hasn't fully responded to the treatment.
CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.
Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.
Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.
The user experienced significant hair regrowth using dutasteride 0.5 mg daily, 5% topical minoxidil twice a day, and microneedling over several months. They also used ketoconazole shampoo and rosemary oil, reporting some side effects but overall positive results.
The user experienced significant hair regrowth after 6 months using oral finasteride, topical minoxidil, and a derma pen once a month. The results were impressive, with many users commenting on the transformation and asking about the specific routine and any side effects.
The conversation discusses using topical dutasteride from minoxidilmax for hair loss and the possibility of crowdfunding for DHT blood tests to check if the treatment goes systemic. The user plans to post before and after pictures.
The conversation discusses the potential benefits of adding Vitamin B6 (P-5-P) to topical hair loss treatments like RU58841, finasteride, or minoxidil. The user suggests that Vitamin B6 might enhance these treatments by naturally lowering scalp prolactin.
The conversation discusses a product called Rexagain Mixprocapil, which includes topical finasteride. Users express skepticism about the product's legitimacy and caution about its use.
A user discussed using finasteride for six months to treat hair loss, noting minimal side effects and uncertain hair regrowth. They mentioned not using minoxidil and considering future options like hair transplants.
A 21-year-old male experienced significant hair regrowth using minoxidil 5% topical, oral finasteride 1mg, derma stamping, and ketoconazole shampoo over several months. He reported no side effects and remains optimistic about further progress.
AHK-cu peptides are discussed for hair growth, with users comparing them to GHK-cu peptides and sharing sources to buy. AHK-cu is noted as more expensive, and users express interest in finding cheaper, reliable vendors.
KX-826 Max combines KX-826, Kopyrrol, and Kopexil as a potential alternative to minoxidil and finasteride for hair loss, but users express skepticism about its effectiveness and high cost. Some users believe traditional treatments like minoxidil, finasteride, and others are more reliable.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.
A user's progress after 6 months of taking finasteride and minoxidil for hair loss, with other users providing comments about the effectiveness of the treatments.
P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.
The conversation discusses hair loss treatments, specifically using 5% minoxidil foam, Vitamin B12, and Vitamin D, with suggestions to add oral finasteride and minoxidil for better results. Concerns about side effects, particularly from finasteride, and the need for a DHT blocker are also highlighted.
A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.
RU58841 caused chest tightness, throat irritation, and headaches, leading the user to stop its use. The user plans to restart with a lower dose if symptoms fully disappear but remains cautious due to anxiety and side effects.
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.